Anti-Human M-CSF Reference Antibody|抗人M-CSF参考抗体(靶标：人巨噬细胞集落刺激因子)
- 货号：RB9THY515016
- 价格：面议
- 点击：446
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Humanized |
| 克隆性 | Monoclonal |
| 抗体亚型 | IgG1-kappa |
| 纯度 | >95% as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1 mg/ml |
| 内毒素水平 | Please contact with the lab for this information. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | CSF1, Macrophage colony-stimulating factor 1, CSF-1, Lanimostim, M-CSF, MCSF |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 表达系统 | Mammalian Cells |
| 登录号 | P09603 |
| 背景信息 | Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited. On 15 October 2014, orphan designation (EU/3/14/1350) was granted by the European Commission to Novartis for recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor for the treatment of tenosynovial giant cell tumor, localized and diffuse type. They conducted a phase 1 study to assess the safety and tolerability of administering single ascending doses and repeat doses of lacnotuzumab to healthy volunteers, and to examine the pharmacokinetics (PK), pharmacodynamics (PD), and mechanistic properties of lacnotuzumab. Nonclinical investigations of the mechanism of action of lacnotuzumab were also performed to explain the observed adverse events (AEs) profile associated with CSF-1 pathway inhibition. Lacnotuzumab was generally well tolerated. The majority of AEs were low grade, no unexpected or novel AEs were observed, and there were no discontinuations for AEs. Lacnotuzumab also showed dose-dependent, on-target effects on multiple downstream biomarkers. Preclinical investigations of the CK elevation and periorbital swelling observed after lacnotuzumab administration suggest that these are reversible, nonpathological events linked to inhibition of the CSF-1 pathway. These data support further evaluation of lacnotuzumab in clinical studies. • Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction., PMID:32286255 • p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression., PMID:37676642 • Pexidartinib: First Approval., PMID:31602563 • Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets., PMID:30930117 • CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment., PMID:34088832 • Osteoclast Differentiation Assay., PMID:30378050 • Colony stimulating factor-1 receptor drives glomerular parietal epithelial cell activation in focal segmental glomerulosclerosis., PMID:38428734 • Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130., PMID:34999736 • Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis., PMID:40020639 • Catechism (Quiz 13)., PMID:34341297 |
| 别名 | MCS-110, 1831128-32-5 |
| 种属 | Human |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品:
| 产品名称 | 点击数 |
|---|---|
| 倍硫磷单抗 | 6348 |
| 多菌灵/阿苯达唑二合一单抗 | 6427 |
| 三氯噻嗪单抗 | 6526 |
| 吡唑醚菌酯单抗 | 6765 |
| 烯酰吗啉单抗 | 6607 |
| 抑霉唑单抗 | 6290 |
| 恶醚唑（苯醚甲环唑）单抗 | 6456 |
| 赛拉嗪（甲苯噻嗪）单抗 | 6476 |
| 辛硫磷单抗 | 6561 |
| 多效唑单抗 | 6443 |
| 对硫磷单抗 | 6641 |
| 丙溴磷单抗 | 6692 |
| 戊唑醇单抗 | 6690 |
| 莠去津单抗 | 6551 |
| 灭蝇胺单抗 | 6230 |
| 尼卡巴嗪代谢物（DNC）单抗 | 6500 |
| 2.4-二氯苯氧乙酸单抗 | 6352 |
| 甲基对硫磷单抗 | 6425 |
| 左旋咪唑单抗 | 6374 |
| 三唑磷单抗 | 6461 |